Intestinal Fistulas Medication
- Author: David E Stein, MD; Chief Editor: Julian Katz, MD more...
As previously stated, it is not yet clear whether medications such as octreotide (a synthetic substitute of somatostatin that suppresses the release of many GI hormones) help to close fistulas. Although contradictory findings on the role of medication in fistula closure have been found, research has shown that octreotide decreases overall fistula output. Immunosuppressive agents used in fistula therapy include azathioprine and infliximab.
These agents inhibit the release of serotonin and the secretion of many hormones involved in GI function.
Octreotide is an inhibitory hormone consisting of 2 peptides (14 amino acids and 28 amino acids in length) secreted by hypothalamus and delta cells of the stomach, intestines, and pancreas. It inhibits the release of growth hormone (GH) and thyroid-stimulating hormone (TSH) and suppresses the release of many GI hormones (gastrin, cholecystokinin, secretin, motilin, vasoactive intestinal polypeptide [VIP], glucose-dependent insulinotropic polypeptide [GIP]).
Octreotide results in decreased gastric emptying and reduces smooth muscle contractions and blood flow in the intestines. It is approved for use in treating acromegaly (since it blocks GH release) and symptoms related to carcinoid syndrome and VIPomas.
These agents inhibit the activity of key factors in the immune system.
Azathioprine is a prodrug that is converted in the body to 6-mercaptopurine (6-MP). A member of a group of medicines called antimetabolites, azathioprine is a chemotherapy medication that inhibits the activity of the immune system, consequently reducing inflammation. Originally developed to treat certain forms of leukemia, the drug has been used to treat some conditions in which the immune system is overly active, such as Crohn disease. Clinical studies of azathioprine therapy have demonstrated a significant improvement in closure rates or improvement of the fistula site compared with placebo.
Infliximab is a monoclonal antibody with murine variable regions that specifically bind human tumor necrosis factor alpha (TNF-alpha), which has important role in promoting inflammation. By blocking the action of TNF-alpha, infliximab reduces signs and symptoms of inflammation. Clinical studies have demonstrated that infliximab significantly improved closure rates of fistulas in patients with Crohn disease and was as effective as maintenance therapy in reducing the number of relapses compared with previous medical treatment therapies.
Elliott TB, Yego S, Irvin TT. Five-year audit of the acute complications of diverticular disease. Br J Surg. 1997 Apr. 84(4):535-9. [Medline].
Berry SM, Fischer JE. Classification and pathophysiology of enterocutaneous fistulas. Surg Clin North Am. 1996 Oct. 76(5):1009-18. [Medline].
Kyle J, Lee ECG, Nolan DJ. Fistulae in Crohn’s Disease. Clinical Surgery International: Surgery of Inflammatory Bowel Disorders. 1987. Vol 14:190-6.
Annibali R, Pietri P. Fistulous complications of Crohn's disease. Int Surg. 1992 Jan-Mar. 77(1):19-27. [Medline].
Lavery IC. Colonic fistulas. Surg Clin North Am. 1996 Oct. 76(5):1183-90. [Medline].
Donner CS. Pathophysiology and therapy of chronic radiation-induced injury to the colon. Dig Dis. 1998 Jul-Aug. 16(4):253-61. [Medline].
Böttger TC, Junginger T. Factors influencing morbidity and mortality after pancreaticoduodenectomy: critical analysis of 221 resections. World J Surg. 1999 Feb. 23(2):164-71; discussion 171-2. [Medline].
Falconi M, Pederzoli P. The relevance of gastrointestinal fistulae in clinical practice: a review. Gut. 2001 Dec. 49 Suppl 4:iv2-10. [Medline].
Pontari MA, McMillen MA, Garvey RH, et al. Diagnosis and treatment of enterovesical fistulae. Am Surg. 1992 Apr. 58(4):258-63. [Medline].
Rots WI, Mokoena T. Successful endoscopic closure of a benign gastrocolonic fistula using human fibrin sealant through gastroscopic approach: a case report and review of the literature. Eur J Gastroenterol Hepatol. 2003 Dec. 15(12):1351-6. [Medline].
Hancock BD. ABC of colorectal diseases. Haemorrhoids. BMJ. 1992 Apr 18. 304(6833):1042-4. [Medline].
Rolandelli R, Roslyn JJ. Surgical management and treatment of sepsis associated with gastrointestinal fistulas. Surg Clin North Am. 1996 Oct. 76(5):1111-22. [Medline].
Pederzoli P, Bassi C, Falconi M, et al. Conservative treatment of external pancreatic fistulas with parenteral nutrition alone or in combination with continuous intravenous infusion of somatostatin, glucagon or calcitonin. Surg Gynecol Obstet. 1986 Nov. 163(5):428-32. [Medline].
Wedell J, Banzhaf G, Chaoui R, et al. Surgical management of complicated colonic diverticulitis. Br J Surg. 1997 Mar. 84(3):380-3. [Medline].
Levy C, Tremaine WJ. Management of internal fistulas in Crohn's disease. Inflamm Bowel Dis. 2002 Mar. 8(2):106-11. [Medline].
Goverman J, Yelon JA, Platz JJ, et al. The "Fistula VAC," a technique for management of enterocutaneous fistulae arising within the open abdomen: report of 5 cases. J Trauma. 2006 Feb. 60(2):428-31; discussion 431. [Medline].
Dorta G. Role of octreotide and somatostatin in the treatment of intestinal fistulae. Digestion. 1999. 60 Suppl 2:53-6. [Medline].
Rahbour G, Siddiqui MR, Ullah MR, et al. A meta-analysis of outcomes following use of somatostatin and its analogues for the management of enterocutaneous fistulas. Ann Surg. 2012 Dec. 256(6):946-54. [Medline].
Amiot A, Setakhr V, Seksik P, et al. Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: a cohort study from the GETAID. Am J Gastroenterol. 2014 Sep. 109(9):1443-9. [Medline].
Greenstein AJ. The surgery of Crohn's disease. Surg Clin North Am. 1987 Jun. 67(3):573-96. [Medline].
Von Koperen PJ, Bemelman WA, Gerhards MF, Janssen LW, van Tets WF, van Dalsen AD, et al. The anal fistual plug treatment compared with the mucosal advancement flap for cryptoglandular high transsphincteric perianal fistula: a double-blinded multicenter randomized trial. Dis Colon Rectum. Apr 2011. 54(4):387-93. [Medline].
Butchberg B, Masoomi H, Choi J, Bergman H, Mills S, Stamos MJ. A tale of two (anal fistula) plugs: is there a difference in short-term outcomes?. Am Surg. Oct 2010. 76(10):1150-3. [Medline].
Zhu YF, Tao GQ, Zhou N, Xiang C. Current treatment of rectovaginal fistula in Crohn's disease. World J Gastroenterol. Feb 2011. 17(8):963f-7. [Medline].
Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 6. 340(18):1398-405. [Medline].
Ellis CN. Sphincter-preserving fistula management: what patients want. Dis Colon Rectum. Dec 2010. (53(12):1652-5. [Medline].
Lindberg E, Jarnerot G, Huitfeldt B. Smoking in Crohn's disease: effect on localisation and clinical course. Gut. 1992 Jun. 33(6):779-82. [Medline].
Meissner K. Late radiogenic small bowel damage: guidelines for the general surgeon. Dig Surg. 1999. 16(3):169-74. [Medline].
Practice parameters for treatment of fistula-in-ano--supporting documentation. The Standards Practice Task Force. The American Society of Colon and Rectal Surgeons. Dis Colon Rectum. 1996 Dec. 39(12):1363-72. [Medline].
Schecter WP. Management of enterocutaneous fistulas. Surg Clin North Am. Jun 2011. 91(3):481-91. [Medline].